Arcutis Biotherapeutics I... (ARQT)
| Bid | 17.16 |
| Market Cap | 2.05B |
| Revenue (ttm) | 192.77M |
| Net Income (ttm) | -137.35M |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | -14.92 |
| Forward PE | -15.55 |
| Analyst | Buy |
| Ask | 17.42 |
| Volume | 2,025,843 |
| Avg. Volume (20D) | 2,304,743 |
| Open | 17.40 |
| Previous Close | 17.01 |
| Day's Range | 16.91 - 17.64 |
| 52-Week Range | 6.99 - 17.70 |
| Beta | 1.49 |
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp ...
Analyst Forecast
According to 6 analyst ratings, the average rating for ARQT stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 12.68% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call TranscriptArcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance & Investor Relations Frank Wata...
